Insulin resistance induced by de novo pathway–generated C16-ceramide is associated with type 2 diabetes in an obese population
Open Access
- 20 February 2022
- journal article
- research article
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 21 (1) , 1-9
Abstract
Background: Obesity and diabetes are two chronic metabolic diseases whose prevalence is increasing at an alarming rate globally. A close association between obesity, diabetes, and insulin resistance has been identified, and many studies have pinpointed obesity as a causal risk factor for insulin resistance. However, the mechanism underlying this association is not entirely understood. In the past decade, ceramides have gained attention due to their accumulation in certain tissues and their suggested role in initiating insulin resistance. This study aims to determine the association of specific ceramides and their major metabolizing enzymes with obesity-associated insulin resistance. Methods: The samples comprised subcutaneous adipose tissues collected from three cohorts: lean non-diabetic (controls; n = 20), obese-non-diabetic (n = 66), and obese-diabetic (n = 32). Ceramide levels were quantified using LC-MS/MS and mRNA expression level for different enzymes were estimated using real-time PCR-based RNA expression analysis. Results: C16-ceramide (P = 0.023), C16-dihydro-ceramide (P < 0.005), C18-dihydro-ceramide (P = 0.009) and C24-ceramide (P = 0.040) levels were significantly increased in the obese cohort compared to the control group. However, stratification of the obese group revealed a significant increase in the C16-ceramide levels (P = 0.027) and mRNA over expression of the serine palmitoyl transferases enzyme subunit SPT1 (P < 0.005) in the obese-diabetic cohort compared to the obese-non-diabetic cohort. Conclusions: The present study indicates that C16-ceramide plays a pivotal role in inducing insulin resistance. Overexpression of SPT1 in the obese-diabetic group and its positive correlation with C16-ceramide suggest that C16-ceramide was generated through the de novo pathway.Keywords
Funding Information
- Deanship of Scientific Research, Imam Abdulrahman Bin Faisal University (2014-128-IRMC)
This publication has 32 references indexed in Scilit:
- Role of ceramide in diabetes mellitus: evidence and mechanismsLipids in Health and Disease, 2013
- Sphingolipid Metabolism and Obesity-Induced InflammationFrontiers in Endocrinology, 2013
- Increased Bioactive Lipids Content in Human Subcutaneous and Epicardial Fat Tissue Correlates with Insulin ResistanceLipids, 2012
- Inhibition of De Novo Ceramide Synthesis Reverses Diet-Induced Insulin Resistance and Enhances Whole-Body Oxygen ConsumptionDiabetes, 2010
- Plasma Ceramides Are Elevated in Obese Subjects With Type 2 Diabetes and Correlate With the Severity of Insulin ResistanceDiabetes, 2009
- Targeting of PKCζ and PKB to caveolin-enriched microdomains represents a crucial step underpinning the disruption in PKB-directed signalling by ceramideBiochemical Journal, 2008
- Adipose Tissue Inflammation and Increased Ceramide Content Characterize Subjects With High Liver Fat Content Independent of ObesityDiabetes, 2007
- Inhibition of Ceramide Synthesis Ameliorates Glucocorticoid-, Saturated-Fat-, and Obesity-Induced Insulin ResistanceCell Metabolism, 2007
- Altered Adipose and Plasma Sphingolipid Metabolism in ObesityDiabetes, 2006
- Ceramide Disables 3-Phosphoinositide Binding to the Pleckstrin Homology Domain of Protein Kinase B (PKB)/Akt by a PKCζ-Dependent MechanismMolecular and Cellular Biology, 2003